- Home
- PHM vs ROIV Comparison
PHM vs ROIV Comparison
Compare PHM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHM | ROIV |
|---|---|---|
| Founded | 1950 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 21.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHM | ROIV |
|---|---|---|
| Price | $128.07 | $31.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $136.23 | $28.94 |
| AVG Volume (30 Days) | 1.2M | ★ 5.6M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | $744.61 |
| P/E Ratio | $68.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $99.45 | $10.71 |
| 52 Week High | $144.50 | $32.79 |
Technical Indicators
Market Signals| Indicator | PHM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 60.76 |
| Support Level | $113.83 | $27.44 |
| Resistance Level | $133.09 | $32.79 |
| Average True Range (ATR) | 3.69 | 0.93 |
| MACD | 0.88 | 0.20 |
| Stochastic Oscillator | 91.08 | 75.99 |
Price Performance
Historical ComparisonAbout PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.